{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Deformity%3B+Skin&page=6",
    "query": {
      "condition": "Deformity; Skin",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 1849,
    "total_pages": 185,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Deformity%3B+Skin&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Deformity%3B+Skin&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T11:36:11.331Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04597385",
      "title": "Long-term Follow-Up for RGX-121",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Mucopolysaccharidosis II"
      ],
      "interventions": [
        {
          "name": "Long-term Follow-Up",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "REGENXBIO Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 27,
      "start_date": "2021-03-14",
      "completion_date": "2028-10",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-10-20T11:36:11.331Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • New Brunswich, New Jersey • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Brunswich",
          "state": "New Jersey"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04597385"
    },
    {
      "nct_id": "NCT01871714",
      "title": "Phenotypic Properties in Individuals Affected With XLHED",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "X Linked Hypohidrotic Ectodermal Dysplasia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Edimer Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2013-05",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2013-11-27",
      "last_synced_at": "2026-10-20T11:36:11.331Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01871714"
    },
    {
      "nct_id": "NCT04177498",
      "title": "Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Recessive Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "Rigosertib Sodium",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 3,
      "start_date": "2021-08-24",
      "completion_date": "2025-05-05",
      "has_results": false,
      "last_update_posted_date": "2025-08-01",
      "last_synced_at": "2026-10-20T11:36:11.331Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04177498"
    },
    {
      "nct_id": "NCT06224348",
      "title": "A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dermatitis Atopic"
      ],
      "interventions": [
        {
          "name": "Amlitelimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Topical corticosteroids",
          "type": "DRUG"
        },
        {
          "name": "Topical calcineurin inhibitors",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 643,
      "start_date": "2024-01-18",
      "completion_date": "2025-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-10-20T11:36:11.331Z",
      "location_count": 40,
      "location_summary": "Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 32 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06224348"
    },
    {
      "nct_id": "NCT02303626",
      "title": "12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Hereditary Angioedema",
        "HAE"
      ],
      "interventions": [
        {
          "name": "BCX4161",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioCryst Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2014-12-17",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2025-11-17",
      "last_synced_at": "2026-10-20T11:36:11.331Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Granada Hills, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Granada Hills",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02303626"
    },
    {
      "nct_id": "NCT04668521",
      "title": "Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Adnexal Mass",
        "Germline BRCA1 Gene Mutation",
        "Germline BRCA2 Gene Mutation",
        "Hereditary Breast and Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "OVA360",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Aspira Women's Health",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 215,
      "start_date": "2020-05-04",
      "completion_date": "2023-12-15",
      "has_results": false,
      "last_update_posted_date": "2023-12-26",
      "last_synced_at": "2026-10-20T11:36:11.331Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04668521"
    },
    {
      "nct_id": "NCT01202149",
      "title": "Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Eczema",
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Elidel (pimecrolimus cream, 1%) Hylatopic Plus Emollient Foam (non-medicated device)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Frankel, Amylynne, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2010-03",
      "completion_date": "2010-11",
      "has_results": false,
      "last_update_posted_date": "2011-04-15",
      "last_synced_at": "2026-10-20T11:36:11.331Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01202149"
    },
    {
      "nct_id": "NCT00438815",
      "title": "Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hereditary Angioedema"
      ],
      "interventions": [
        {
          "name": "C1 esterase inhibitor [human] (C1INH-nf)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Year and older"
      },
      "enrollment_count": 113,
      "start_date": "2006-09-21",
      "completion_date": "2009-03-31",
      "has_results": true,
      "last_update_posted_date": "2021-06-08",
      "last_synced_at": "2026-10-20T11:36:11.331Z",
      "location_count": 30,
      "location_summary": "Scottsdale, Arizona • Bentonville, Arkansas • Los Angeles, California + 27 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00438815"
    },
    {
      "nct_id": "NCT00006393",
      "title": "Genetic Study of the FBN1 Gene and Fibrillin-1 Abnormalities in Choctaw Native Americans and Other Patients With Systemic Sclerosis",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Systemic Sclerosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Center for Research Resources (NCRR)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "0 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "1998-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-20T11:36:11.331Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006393"
    },
    {
      "nct_id": "NCT02324049",
      "title": "Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Mucopolysaccharidosis IIIB"
      ],
      "interventions": [
        {
          "name": "SBC-103",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "2 Years to 12 Years"
      },
      "enrollment_count": 11,
      "start_date": "2015-01-22",
      "completion_date": "2017-10-16",
      "has_results": true,
      "last_update_posted_date": "2018-08-21",
      "last_synced_at": "2026-10-20T11:36:11.331Z",
      "location_count": 2,
      "location_summary": "Minneapolis, Minnesota • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02324049"
    }
  ]
}